TRPA1
ENSG00000104321
Target class
Ion channel
Chromosome
8
Approved drugs
3
Clinical candidates (approved and in development)
4
- Approved drugs
- 3
- Clinical candidates (approved and in development)
- 4
- Chemical probe available
- Yes
- Target name
- TRPA1
- Gene name
- Transient receptor potential cation channel subfamily A member 1
- Gene symbol
- TRPA1
- Previous gene symbols
- ANKTM1
- Protein name
- Transient receptor potential cation channel subfamily A member 1 (Ankyrin-like with transmembrane domains protein 1) (Transformation-sensitive protein p120) (p120) (Wasabi receptor)
- Gene biotype
- Protein coding
- Gene family
- Transient receptor potential cation channels|Ankyrin repeat domain containing
- Target class
- Ion channel
- Target type
- Human gene
- Tissues expressed in
- 5
- Highest tissue expression
- 12.11
- Tissue specificity (Gini)
- 0.882
- Tissue specificity (tau)
- 0.949
- KEGG gene identifiers
- hsa:8989
- Reactome pathways
- R-HSA-3295583
- Protein interaction confidence
- 0.794765
- Protein interaction partners
- 34
- End position
- 72089998
- Start position
- 72019608
- Chromosome
- 8
- Strand
- Reverse
- Cell membrane
- Multi-pass membrane protein .
- PubMed 20547126
- PubMed 21873995
- PubMed 25389312
- PubMed 25855297
- PubMed 31866091
- Tissue specificity (tau)
- 0.948662
- Expression inequality (Gini)
- 0.881771
Expression in transcripts per million
- Bladder
- 12.11
- Small Intestine - Terminal Ileum
- 9.27
- Cells - Cultured fibroblasts
- 7.88
- Colon - Transverse
- 6.43
- Stomach
- 4.96
Expression in transcripts per million
- Bladder12.11
- Small Intestine - Terminal Ileum9.27
- Cells - Cultured fibroblasts7.88
- Colon - Transverse6.43
- Stomach4.96
- Esophagus - Mucosa0.88
- Testis0.49
- Cervix - Ectocervix0.29
- Colon - Sigmoid0.25
- Cells - EBV-transformed lymphocytes0.23
- Artery - Aorta0.21
- Artery - Coronary0.2
- Vagina0.2
- Cervix - Endocervix0.19
- Esophagus - Muscularis0.15
- Esophagus - Gastroesophageal Junction0.12
- Artery - Tibial0.11
- Spleen0.08
- Ovary0.08
- Brain - Frontal Cortex (BA9)0.07
- Brain - Cortex0.07
- Lung0.06
- Uterus0.06
- Fallopian Tube0.05
- Adipose - Visceral (Omentum)0.05
And 29 more, listed on the interactive page.
- GO:0006811
- GO:0006874
- GO:0009409
- GO:0019233
- GO:0051289
- GO:0070301
- GO:0070588
Cellular components
- GO:0005886
- GO:0005262
- GO:0015267
- GO:0015278
- GO:0042802
- GO:0097604
Related records
Trials (863)
- "EASY EFFECTIVE SMOKELESS" With NICORETTE®
- 4 mg Nicotine Polacrilex Gum and Swedish Portion Snus
- 5HT3 Antagonism and Auditory Gating in Schizophrenia
- A Bioequivalence Study Between Two Nicotine Replacement Therapies in Adult Healthy Smokers Motivated to Quit.
- A Bioequivalence Study of 21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers
- A Bioequivalence Study of Two Nicotine Lozenges in Fasting Conditions in Healthy Smokers
- A Cardiac Safety Study of an Investigational Drug to See How if Affects the Heart in People With Parkinson's Disease Complicated by Motor Fluctuations "OFF" Episodes
- A Clinical Trial to Study the Effects of GRC 17536 in Patients With Painful Diabetic Neuropathy (Painful Extremities Due to Peripheral Nerve Damage in Diabetic Patients)
- A Comparative Effectiveness & Long Term Health Study in Wisconsin Smokers
- A Comparative Effectiveness RCT of Optimized Cessation Treatments
- A Cost-effectiveness Study of Nicotine Patches Distributed Through a Quitline
- A Laboratory Model of Increasing Delta-9-tetrahydrocannabinol (THC) Potency on Cigarette Smoking
- A Multicenter Efficacy Study of a Diclofenac+Menthol Gel in Subjects With Ankle Sprain
- A Pharmacokinetic Evaluation of Two Nicotine Patches in Smokers
- A Phase I/II Study to Evaluate Single Agent and Combination Therapy With Megestrol Acetate and Dronabinol for the Treatment of HIV-Wasting Syndrome
- A Pilot Drug Trial That Evaluates the Whitening Potential of Nicotine Gum
- A Pilot Randomized Controlled Trial of Financial Incentives, Text Messaging, and Usual Care for Homeless Smokers
- A Pilot Study of Dronabinol for Adult Patients With Primary Gliomas
- A Proof-of-concept Clinical Trial Assessing the Safety of the Coordinated Undermining of Survival Paths by 9 Repurposed Drugs Combined With Metronomic Temozolomide (CUSP9v3 Treatment Protocol) for Recurrent Glioblastoma
- A Quit Smoking Study Using Smartphones
Drugs (22)
- Allicin
- Allyl isothiocyanate
- Antipyrine
- Apomorphine
- Auranofin
- Butamben Transient receptor potential cation channel subfamily A member 1 inhibitor
- Butamben picrate Transient receptor potential cation channel subfamily A member 1 inhibitor
- CB-189625 Transient receptor potential cation channel subfamily A member 1 antagonist
- Dibutyl phthalate
- Dronabinol
- GDC-0334
- GRC-17536 Transient receptor potential cation channel subfamily A member 1 antagonist
- Levomenthol
- Menthol Transient receptor potential cation channel subfamily A member 1 opener
- Metamizole
- Nicotine
- Ozone
- Propyphenazone
- RG6341
- Salirasib